RE: Sweetbiotix is as good if not better than we hoped26 Jun 2026 09:38
SweetBiotix fiber, developed by OptiBiotix Health in partnership with DSM-Firmenich, is currently in the late stages of commercial scale-up. OptiBiotix has secured joint development and commercialisation agreements with DSM-Firmenich, but there is no finalized regulatory approval for market launch as of June 2026.The regulatory and market rollout process is actively ongoing.
Key updates include:Development Pipeline: The large-scale manufacturing process is scaling up to meet projected commercial demand.Regulatory Pathway: DSM-Firmenich is reviewing the global regulatory, nutritional, and taste acceptability of SweetBiotix across multiple international territories.Corporate
Milestones: OptiBiotix filed new patents on its improved enzymatic processes to boost yields and purity. In May 2026, the company hosted investor showcases to demonstrate the finished products.
Partner Contracts: Under the 2022 Joint Development Agreement, DSM-Firmenich and OptiBiotix are preparing for targeted commercial launches, with six-figure milestone payments triggered upon market approvals (US/Europe/Asia).